IDEXX Laboratories, Inc. (NASDAQ:IDXX) Receives $552.38 Consensus Target Price from Brokerages

Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $552.38.

A number of equities analysts have weighed in on IDXX shares. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $510.00 to $500.00 and set a "hold" rating on the stock in a report on Thursday, October 10th. Piper Sandler reaffirmed a "neutral" rating and set a $435.00 price objective (down previously from $520.00) on shares of IDEXX Laboratories in a research report on Monday, November 4th. Barclays reduced their price target on shares of IDEXX Laboratories from $570.00 to $481.00 and set an "overweight" rating for the company in a research note on Monday, November 4th. JPMorgan Chase & Co. cut their target price on shares of IDEXX Laboratories from $630.00 to $575.00 and set an "overweight" rating for the company in a research note on Friday, October 11th. Finally, StockNews.com raised shares of IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Thursday.

IDEXX Laboratories Stock Down 0.0 %

Shares of IDEXX Laboratories stock traded down $0.01 during trading hours on Friday, reaching $421.75. 338,565 shares of the company were exchanged, compared to its average volume of 505,750. The firm has a market cap of $34.54 billion, a PE ratio of 40.67, a PEG ratio of 3.68 and a beta of 1.36. The stock's fifty day moving average is $453.61 and its 200 day moving average is $478.67. The company has a debt-to-equity ratio of 0.32, a quick ratio of 1.03 and a current ratio of 1.42. IDEXX Laboratories has a 1 year low of $398.50 and a 1 year high of $583.39.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last announced its quarterly earnings data on Thursday, October 31st. The company reported $2.80 EPS for the quarter, beating analysts' consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same quarter last year, the firm earned $2.53 earnings per share. The firm's revenue was up 6.6% compared to the same quarter last year. As a group, equities research analysts forecast that IDEXX Laboratories will post 10.43 earnings per share for the current year.

Institutional Trading of IDEXX Laboratories

Several hedge funds and other institutional investors have recently made changes to their positions in IDXX. Chicago Partners Investment Group LLC boosted its stake in shares of IDEXX Laboratories by 16.7% in the 3rd quarter. Chicago Partners Investment Group LLC now owns 672 shares of the company's stock worth $340,000 after buying an additional 96 shares during the last quarter. Manning & Napier Advisors LLC bought a new stake in shares of IDEXX Laboratories during the second quarter valued at approximately $20,418,000. Oppenheimer Asset Management Inc. raised its stake in IDEXX Laboratories by 13.8% in the second quarter. Oppenheimer Asset Management Inc. now owns 11,957 shares of the company's stock worth $5,825,000 after buying an additional 1,453 shares in the last quarter. National Pension Service raised its stake in IDEXX Laboratories by 7.3% in the third quarter. National Pension Service now owns 185,972 shares of the company's stock worth $93,957,000 after buying an additional 12,647 shares in the last quarter. Finally, EFG Asset Management Americas Corp. increased its position in shares of IDEXX Laboratories by 45.3% during the second quarter. EFG Asset Management Americas Corp. now owns 12,728 shares of the company's stock worth $6,201,000 after purchasing an additional 3,966 shares in the last quarter. Hedge funds and other institutional investors own 87.84% of the company's stock.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.